<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Rapid Antigen-based SERS assay for COVID-19 Detection (COVID-19)</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>12/01/2020</AwardEffectiveDate>
<AwardExpirationDate>08/31/2021</AwardExpirationDate>
<AwardTotalIntnAmount>255468.00</AwardTotalIntnAmount>
<AwardAmount>255468</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Alastair Monk</SignBlockName>
<PO_EMAI>amonk@nsf.gov</PO_EMAI>
<PO_PHON>7032924392</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact and commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to allow testing of potential COVID-19 patients using a rapid and highly accurate diagnostic test, particularly for patients who are asymptomatic. This will provide a significant advantage in “flattening the curve” of the number of cases by preventing these patients from inadvertently infecting their family and community members. Current protocols require days to return a result, creating problems for public health.  This test, the first of many that can be produced using the underlying platform technology, would improve: 1) the ability to rapidly identify patients with active COVID-19 cases for expeditious clinical intervention, reducing transmission by that patient; and 2) outcomes because of the higher performance and accuracy. &lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase I project addresses the lack of rapid, accurate testing for COVID-19 in near patient settings. This effort will develop an infectious disease platform that combines: 1) DNA aptamers, a recognition element for target proteins; 2) surface enhanced Raman scattering (SERS), a vibrational spectroscopic detection method; 3) and orthogonal partial least squares differential analysis, a well-established statistical method often applied to vibrational spectroscopy-based analyses. By employing aptamers that target SARS-CoV-2 related proteins (e.g. the spike (S) protein), this assay is anticipated to identify the presence of this protein under 30 minutes after oro- or naso-pharyngeal sample is collected, and is ultimately expected to achieve &gt;95% clinical sensitivity and specificity.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>11/30/2020</MinAmdLetterDate>
<MaxAmdLetterDate>11/30/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2031056</AwardID>
<Investigator>
<FirstName>Joel</FirstName>
<LastName>Tabb</LastName>
<PI_MID_INIT>S</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Joel S Tabb</PI_FULL_NAME>
<EmailAddress>j.tabb@ionicasci.com</EmailAddress>
<PI_PHON>6266763076</PI_PHON>
<NSF_ID>000741030</NSF_ID>
<StartDate>11/30/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Ionica Sciences</Name>
<CityName>Ithaca</CityName>
<CountyName>TOMPKINS</CountyName>
<ZipCode>148537202</ZipCode>
<PhoneNumber>6266763076</PhoneNumber>
<StreetAddress>414 Weill Hall</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>New York</StateName>
<StateCode>NY</StateCode>
<CONGRESSDISTRICT>23</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>NY23</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>078861438</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>IONICA SCIENCES, INC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Ionica Sciences]]></Name>
<CityName>Ithaca</CityName>
<CountyName>TOMPKINS</CountyName>
<StateCode>NY</StateCode>
<ZipCode>148537202</ZipCode>
<StreetAddress><![CDATA[414 Weill Hall]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>New York</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>23</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>NY23</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>090E</Code>
<Text>Chem/Bio and Physical Diagnostics</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~255468</FUND_OBLG>
</Award>
</rootTag>
